Skip to main content
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. — Investor Relations & Filings

Ticker · CLDX ISIN · US15117B2025 LEI · 529900F018DMYWH38923 US Manufacturing
Filings indexed 998 across all filing types
Latest filing 2026-04-29 Annual Report
Country US United States of America
Listing US CLDX

About Celldex Therapeutics, Inc.

https://celldex.com/

Celldex Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies. The company's research focuses on the intersection of mast cell biology and immunology to treat severe inflammatory, allergic, and autoimmune diseases. Its lead program is barzolvolimab, a humanized monoclonal antibody that inhibits KIT, a receptor tyrosine kinase essential for the function and survival of mast cells. By targeting this core pathological driver, Celldex aims to provide a best-in-class treatment option. The company leverages proprietary antibody programs and technologies supported by in-house discovery and development capabilities to advance its pipeline.

Recent filings

Filing Released Lang Actions
ARS - Celldex Therapeutics, Inc. (0000744218) (Filer)
Annual Report
2026-04-29 English
DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)
Regulatory Filings
2026-04-02 English
424B5 - Celldex Therapeutics, Inc. (0000744218) (Filer)
Prospectus
2026-04-01 English
10-K - CELLDEX THERAPEUTICS, INC. (0000744218) (Filer)
Annual Report FY 2025
2026-02-25 English
8-K - CELLDEX THERAPEUTICS, INC. (0000744218) (Filer)
Regulatory Filings
2026-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.